Clinical RisksRisks to an investment in Dianthus Therapeutics are primarily clinical, regulatory, and commercial in nature.
Regulatory RisksThe FDA is reviewing severe worsening of CIDP with argenx’s Vyvgart Hytrulo, creating potential challenges for differentiation of active C1s inhibitors in the disease.
Study LimitationsThe study has the caveats of a small sample size and open-label study design, which may impact the robustness of the findings.